CD274 and non-small cell lung carcinoma: Not only the NCCN guidelines but also the American Society of Clinical Oncology (ASCO) and Ontario Health Cancer Care (CCO) NSCLC expert panels made recommendations for therapy for patients without driver alterations based on PD-L1 expression (9, 34).